Stock fact sheet · data as of

Abpro Holdings, Inc. (ABPO): fair value, margin of safety and Wheel Score

Healthcare · Biotechnology · United States · Speculative / Distressed

Close0.4080
GLS fair value13.184 of 9 models
Margin of safety+97%price below fair value
Wheel Score39No optionscapped: no options
Health3/9Piotroski F-score
Moat0.9/10GLS 10-year score
Market cap$2M5k shares a day
Implied vol.-no listed options
P/E1.2EPS 0.34
Dividend yieldnone
Beta0.14moves less than the market
Next earnings2 Dec 2026in 47 days

Is ABPO undervalued?

At 0.4080 (close of 16 Oct 2026), ABPO trades 97% below the GLS average fair value of 13.18. That average comes from 4 models run on the latest filings, and 4 of them land above the current price. Margins of safety over 30% are the exception rather than the rule across the ~7,400 stocks we value each night, so the number earns Abpro Holdings, Inc. the full Value points in the Wheel Score - and a closer look at what the market is pricing in.

The 4 models disagree widely: EPV gives 3.79 while GLS Growth gives 20.88. A spread that wide means the average is sensitive to which methods you trust; the model table below shows where each one lands, and the Quote page lets you switch any of them off.

The nightly engine files ABPO under Speculative / Distressed - negative earnings or a Piotroski score of 3 or less - which caps its Wheel Score at 45 and keeps it out of the Sunday Scan.

Nine valuation models for ABPO

Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.

ModelValuevs priceWhat it measures
DCF--Present value of the projected free cash flows, discounted at the cost of capital; no value tonight
Graham Number--The most a defensive investor pays for the earnings and book value per share; no value tonight
Graham Growth19.51+4682%Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields
Lynch8.53+1990%EPS × the earnings growth rate (PEG of 1), growth capped at 25%
GLS Growth20.88+5018%EPS compounded ten years at the blended growth rate, discounted back at 15% a year
10 Cap--Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight
Payback Time--Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight
DDM--Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight
EPV3.79+829%Earnings power value: current EPS capitalised at 9% with no growth
Zombie (liquidation)0.1520-63%Current assets less all liabilities, per share: the balance-sheet floor. Not in the average
Wall St target0.0000-100%Analysts' average 12-month price target. Not in the average

Quality and financial health

Financial health is weak: ABPO passes 3 of the nine Piotroski tests. Our screens drop the stock at the health rule; a low score is often the reason a stock looks cheap on the valuation models. The GLS Moat score is low at 0.9 out of 10, which says the ten-year record of revenue, earnings, margins and returns on capital has been inconsistent - growth and shocks rather than steady compounding.

Returns on capital are thin or negative - ROIC -1967.3%, ROE 0.0%, ROA -272.1% - with debt at 0.00 times equity and negative free cash flow.

Abpro Holdings, Inc. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain.

Institutional ownership scores 1/10, insider activity 5/10 and Congressional trading 5/10 on the GLS smart-money scales.

Piotroski F-score3 / 9ROIC-1967.3%
GLS Moat0.9 / 10ROE0.0%
Debt / equity0.00ROA-272.1%
Free-cash-flow yield-250.9%Payout ratio0%
Institutions1 / 10Insiders · Congress5 · 5 / 10

Wheel Score 39: No options

ABPO has no listed options in the nightly snapshot, so there is nothing to sell and the stock cannot be wheeled however good the business; the Wheel Score is capped at 39 and shown as "No options" (39 here). The valuation and quality numbers still apply to owning the shares outright.

Volume runs at 5k shares a day on a market cap of $2M, with a beta of 0.14 - a low beta, so day-to-day moves are smaller than the market's; the Stability part of the Wheel Score gives that 6 of 20.

PartPointsFrom
Value25 / 2597% margin of safety
Health7 / 20Piotroski 3/9
Moat1 / 15moat 0.9/10
Premium0 / 20no option data
Stability6 / 205k shares/day, $2M cap, beta 0.14

The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.

Upcoming events

The next earnings report is due on 2 Dec 2026, 47 days away - outside the window of a 30-45-day put sold today.

Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.

Similar stocks in Biotechnology

The 12 companies below are the closest to Abpro Holdings, Inc. by market cap within the Biotechnology industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.

StockCloseFair valueMoSWheelMkt cap
CPMV
Mosaic ImmunoEngineering Inc.
0.3330--23No options$2M
CANF
Can-Fite BioPharma Ltd.
1.85--30No options$2M
ACUT
Accustem Sciences Inc.
0.1474--23No options$2M
ELAB
PMGC Holdings Inc.
3.04846.90+100%39No options$2M
KAPA
Kairos Pharma, Ltd.
0.67061.64+59%39No options$2M
CLDI
Calidi Biotherapeutics, Inc.
0.87019.22+91%33No options$2M
MBIO
Mustang Bio, Inc.
0.38612.93+87%33No options$3M
GOVX
GeoVax Labs, Inc.
0.25780.3517+27%34No options$3M
VRAX
Virax Biolabs Group Limited
1.6514.57+89%38No options$2M
VIVS
VivoSim Labs, Inc.
0.16091.68+90%38No options$3M
VCNX
Vaccinex, Inc.
1.00--30No options$3M
ISCO
International Stem Cell Corporation
0.27001.32+80%39No options$2M

⚖ Compare ABPO with 7 of them   All Healthcare stocks →

Screen the whole market the same way

A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.

Start free See the Sunday Scan

Questions about ABPO

Is ABPO undervalued right now?

By the GLS models, yes: at 0.4080 the stock is 97% below the average fair value of 13.18 (data as of 16 Oct 2026). Whether the discount is deserved is the question to research next.

What is the Wheel Score of ABPO and what does it mean?

ABPO has no listed options in our nightly snapshot, so it cannot be wheeled; its Wheel Score is capped at 39 and shown as "No options".

What is the GLS fair value for ABPO?

13.18 per share as of 16 Oct 2026 - the simple average of the 4 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.

When does Abpro Holdings, Inc. report earnings next?

The next earnings report is due on 2 Dec 2026, 47 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.

Does ABPO have listed options, and how liquid are they?

No. The nightly options snapshot found no listed contracts on ABPO, so the wheel strategy cannot be run on it and the Wheel Score is capped at 39.

Data as of 16 Oct 2026: prices and fundamentals from Financial Modeling Prep, option data from Polygon; valuations, scores and the Wheel Score by GLS Equity's models, run nightly. Prices in USD; the close shown is the previous session's. Everything on this page is general information produced by automated models from third-party data - not a recommendation to buy, sell or trade any security or option, and not financial advice. Past performance is not indicative of future results. GLS Equity provides data and tools, not financial advice.